28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
The timing of palliative care initiation may be more appropriately directed using a needs-based approach, instead of a prognostically driven one. 1 key finding →
Participants: 20 Evidence: low
Full summary, score breakdown and related studies → Original source
The AD-HHK-S included 28 true/false items assessing 3 areas of knowledge: knowledge about hospice, knowledge about home hospice, and knowledge about home hospice for AD. 5 key findings →
Participants: 28 Evidence: low
Full summary, score breakdown and related studies → Original source
Receiving any home health care in the last 3 years of life was associated with a lower probability of inpatient death without hospice (Pr 23.3% vs 31.5%, p < .001), and this effect was stronger when home health care began prior to versus during the last year of life (Pr 22.5% vs 24.3%, p < .001). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
While amyloid precursor protein and the microtubule-associated protein tau demonstrated higher abundance in AD brains, no significant race-related differences were observed. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Reactions to disclosure did not significantly differ among participant groups based on self-reported race and ethnicity. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Obesity is a significant health crisis affecting more than 123 million adults and children/adolescents in the US. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia research lacks appropriate representation of diverse groups who often face substantial adversity and greater risk of dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Compared to non-Hispanic or Latino (NH) White participants, Hispanic or Latino (3.52 points, 95% confidence interval [CI]: [2.61, 4.42]); NH Asian (2.97 points, 95% CI: [1.71, 4.22]); and NH Black participants (2.79 points, 95% CI: [1.96, 3.63]) participants demonstrated higher levels of endorsement of the VPAI items at baseline. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The nature and outcome of family caregiving is different for various racial and ethnic groups. 1 key finding →
Participants: 26 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer disease (AD) is a growing public health problem that disproportionately affects racial and ethnic minorities, including African Americans. 2 key findings →
Participants: 301 Evidence: low
Full summary, score breakdown and related studies → Original source
When using ethnic group-specific norms, NP and functional abilities predicted diagnosis in both groups with no significant differences but BPS was only significant in Hispanics. 5 key findings →
Participants: 444 Evidence: low
Full summary, score breakdown and related studies → Original source
3,001,987 Medicare beneficiaries were identified, of which 8.2% had a dementia diagnosis. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Of 2 684 704 Fee-for-Service patients with Alzheimer dementia, 769 141 met all inclusion criteria; among these, 281 042 (36.5%) had agitation. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This study evaluates whether patients enrolled in trials of aducanumab, EMERGE and ENGAGE, were representative of patients with dementia enrolled in Medicare by estimating the proportions of Medicare beneficiaries with Alzheimer disease (AD) or mild cognitive impairment (MCI) who would have been excluded from these trials. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Among 88 African Americans with cognitive impairment (mean = 10 years follow-up), Medicare claims identified dementia <2 years from cohort diagnosis in 55%; 27% were identified 2-9.9 years after cohort diagnosis, and in 18% there was either no claims diagnosis during the study period, or claims identified dementia 10+ years after cohort diagnosis. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Out of pocket expenditures by families (N = 182) of relatives with dementia residing in the community were examined. 3 key findings →
Participants: 182 Evidence: low
Full summary, score breakdown and related studies → Original source
A total of 12,764,487 weighted older adults with ADRD were included, with 34.60% of them using anti-dementia drugs. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
It might constitute a simple, cost-effective and reproducible in vivo proxy of AD suitable to be adopted worldwide not only in daily clinical practice but also in future experimental trials, to avoid the enrolment of misdiagnosed AD patients. 1 key finding →
Participants: 526 Evidence: low
Full summary, score breakdown and related studies → Original source
An MCI-like hypometabolic pattern was documented in 5 patients (7%) by SVA and 7 patients (10%) by SPM analysis; however, only 2 of these patients were selected by both methods. 4 key findings →
Participants: 71 Evidence: low
Full summary, score breakdown and related studies → Original source
c GMP , and not c AMP levels, were significantly lower in the CSF of patients diagnosed with mild AD when compared with nondemented controls. 5 key findings →
Participants: 79 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Efforts to delay onset of dementia, if successful, would likely benefit older adults of all ages. 5 key findings →
Participants: 3,605 Evidence: low
Full summary, score breakdown and related studies → Original source
This molecular genetics study found that several TREM2 gene variants previously thought to work only by altering the TREM2 protein itself, also disrupt how the TREM2 gene's RNA message is spliced together, sometimes producing dysfunctional protein versions. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
This is primarily a mouse-model study (in amyloid-plaque mouse models such as 5xFAD, with some human tissue validation) identifying a newly recognized, protective state of brain immune cells (microglia) that expresses genes normally associated with the immune system's lymphocytes. 4 key findings →
Evidence: early
Full summary, score breakdown and related studies → Original source
Donanemab provides clinical benefits but is unlikely to be cost-effective under current Australian thresholds. 3 key findings →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The results project substantial cost savings from implementing a blood test for AD pathology within the diagnostic pathway based on modeling results, which future research should confirm with actual data. 4 key findings →
Design: modelling Evidence: preliminary
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →